appears to have contributed to hyperbilirubinemia in the first days after transplantation. A patient with CML in accelerated phase received G-CSF-mobilized PBPC from an unrelated HLA genoCase report typically matched donor. The blood groups of the patient and donor were bidirectionally incompatible.
tation. Mononuclear cells were isolated by density gradient sedimentation. DNA was extracted according to standard procedures. For chimerism analysis we used the AmpliType PM kit (Perkin Elmer, Branchburg, USA) specific for the detection of six hypervariable regions (HVRs) in the human genome performed by PCR. The amplification products were fractionated by an 8% polyacrylamide gel and visualized by ethidium bromide staining. Individual genetic patterns of donor and recipient were detected and compared before and in the follow-up after PBPC transplantation. 
Alloenzymes

Results
The graft contained 5.6 × 10 8 nucleated cells (NC)/kg (6.0 × 10 6 CD34-positive NC/kg, 2.7 × 10 8 CD3-positive T lymphocytes and 5 × 10 5 CFU-E/kg). Five milliliters of packed red blood cells were transfused with the enriched fraction. engraftment was fast with Ͼ500 PMN/l on day +9 and Ͼ20 000/l platelets on day +13. G-CSF was discontinued on day +12.
GVHD prophylaxis was 5 mg/kg cyclosporin A i.v. a and Anti-A 2 (1:2) were found on day +20. Anti-A 1 declined to 1:4 on day +45 whereas Anti-A 2 stayed at the same level. day and MTX (15 mg/m 2 day + 1, 10 mg/m 2 day + 3). Five days after transplantation hyperbilirubinemia with a
The direct antiglobulin test was positive on day +12 and became negative on days +17 and +20. Reticulocytes were conjugated fraction of 50% developed. No MTX was administered on day +6 or +11. From days +6 to +8 the elevated throughout (Figure 2 ). On day +13 complete donor-type engraftment was patient experienced fever (40°C) and chills which were resistant to antipyretics. Empiric antibiotic and antimycotic detected by PCR for the first time. Phenotypic analysis of enzymatic polymorphism on day therapy was initiated. A maximum bilirubin level of 18 mg/dl and a peak in LDH with 1041 U/l was reached on +27 revealed mixed chimerism for phosphoglyceratmutase (RBC and WBC) and uridinmonophosphatkinase (WBC). day +14, whereas the haptoglobin level fell below the detection limits (Figure 1) . Simultaneously, hemoglobin These two enzymatic systems had been of a different phenotype in donor and recipient. levels and erythrocytes declined rapidly. Ten units of washed group O RBC were given during the next 6 days Up to day 25, the bilirubin declined to 2.3 mg/dl. GVHD grade IV involving gut and skin developed on day 19 and (Figure 2 ). Bedside testing of the patient's RBC with monoclonal mouse IgM-antibodies (Anti-A, Anti-B, SIFIN; immunosuppression was intensified. After 14 days of treatment with OKT 3 and high doses of steroids, stool volume Berlin, Germany) on day +16 revealed agglutination with anti-B.
declined and predisolone was tapered to 1.5 mg/kg on day 45. On day 55, the patient experienced sudden loss of Blood typing showed two RBC populations: transfused O RBC and donor type B RBC, with disappearance of the vision and a CT scan of the head revealed massive cerebral hemorrhage into a pre-existing abscess. Progressive respirrecipient cell population. Relevant titers of Anti-A 1 (1:16) atory insufficiency followed and he died on day 58. VOD or GVHD was not possible because of low platelet counts. After day 12, GVHD of the liver which may appear Autopsy was refused.
earlier in allogeneic PBPC transplantation may have contributed to the increase of direct bilirubin levels.
Discussion
We suspect that early immune hemolysis was caused by the antibodies mentioned, which were a product of the large The first reports of allogeneic transplantation of G-CSFamount of passively transfused donor lymphocytes. Further mobilized PBPC have shown rapid and, until now, stable data on allogeneic PBPC transplantation are necessary to engraftment.
1 In siblings, acute GVHD seems to be compainvestigate the role of blood group incompatibility in this rable to the experience with BMT.
2 Addition of G-CSFsetting. mobilized, T cell-depleted PBPC to BM seems feasible in haploidentical siblings without a significant incidence of severe GVHD. The detection of donor-type erythrocytes on day +16
